Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T, Zamami Y, Miyata K, Mikami T, Asada M, Fukushima K, Yoshino M, Mitsuboshi S, Okada N, Hamano H, Sakurada T, Matsuoka-Ando R, Aizawa F, Yagi K, Goda M, Chuma M, Koyama T, Izawa-Ishizawa Y, Yanagawa H, Fujino H, Yamanishi Y, Ishizawa K.
Niimura T, et al. Among authors: asada m.
J Clin Pharmacol. 2023 Apr;63(4):473-479. doi: 10.1002/jcph.2187. Epub 2022 Dec 21.
J Clin Pharmacol. 2023.
PMID: 36453166